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ATGGCCCTGGATCTTCTTTCATCCTACGCTCCTGGCTTGGTCGAAAGCCTGCTAACATGGAA 
AGGCGCAGCCGGCTTGGCTGCAGCTGTTGCCCTGGGCTATATTATTATAAGCAACCTTCCTG 
GAAGGCAGGTTGCTAAGCCCAGCCTTCTTCAAGTCAGAACTGGTGGCGTCGCCTTCGAGAAG 
GTCGCTGAGGTAGTTGCCGACTACAGTGACTCTTACGGGCAAACTGAAAAGGGCGAACTCAT 
CGTCAAGGACAACAACAAGATTGTCTCTCTCGCGAATACTTTCTATGACCTCATCACCGATG 
GATATGAGTGGGGATGGGGCTCCGGCTTCCACTTCTCTCATAGGCTGCCAGGGATGTCCTTC 
AATGCATCTCAGCTGCTCCATGAGTCCCGTATGGCGTCTTTCCTGCGCCTGAAGCCCGGCAT 
GCAAGTTCTTGATGTTGGCTGCGGTGTCGGAAACCCTGGCAGAACGGTTGCTGCCTGCAGTG 
GAGCAGTGGTGACTGGCATCACCATCAATGCATACCAGATCAAGCGCGCTGAGTTGCACACT 
AAGCGGGCGGGCTTGGTAGGATACTTCAAGCCAGTTCAGGGAAACTTCTGCGCGATGCCTTT 
CCAAGACAAGAGCTTCGATGCTGCCTTTGCCATGGACTCTACTTGCCATGCCCCCAAGCTGG 
AGGATGTGTACTCCGAGGTCTTCCGCGTGTTGAAGCCTGGCGCATACTTTGCAACTTATGAG 
TGGGTGTCTACAAAGAACTACGACTCCAACAACCCAGAGCACGTGAAGTGCATGAACAGCAT 
CATCCTGGGCAATGGCCTGCCGAACATCAGGAGTTGGAAGCAAGCTGAGGAGGCAGGGAAGA 
ACGTGGGTTTCAACCTGCTTACCAGCCTCGACATGGCTACAAACTCCCCCATCGGAAAGCCC 
TGGTACTCTGTCCCAGAGCGCATGGTAAACTGGGGCCTGTTCCGTTTCCACAAGGCTTGCAT 
TCGCACTGCCTCTACCCTGCATCTGCTGCCGCCAGAATCCTGGAAGTTCTTCTACATCCTTG 
CAGAGATGGCCGAGAACCTTGTAAAGGGTGGGCAATGGGACATCTTCACCCCCATGCACTTG 
CTGATCTTCCAAAAGCCAGAGTAA 
FIG. 1 
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B. BRAUNII, RACE B GENE FOR A 
TRITERPENE METHYLTRANSFERASE 
ENZYME AND USES THEREOF 
FIELD OF THE INVENTION 
The invention relates to triterpene methyltransferase and 
its use in producing methylated triterpenes. 
BACKGROUND OF THE INVENTION 
Squalene and botryococcene are related by their putative 
biosynthetic origins from the condensation of two famesyl 
diphosphate (FPP) molecules, a common biosynthetic inter 
mediate found in the mevalonate biosynthetic pathway, and 
are known to be synthesized by Bolryococcus braunii, race B, 
a fresh water algae (Okada et al., J. Appl. Phycology, 7: 
555-559, 1995; Metzger et al., Appl. Microbiol. Biolech., 66: 
486-496, 2005). Bolryococcus braunii is known for its ability 
to accumulate large amounts of hydrocarbons. In particular B. 
braunii race B can accumulate 20-50% its dry weight of 
C30-C34 botryococcenes and squalenes. 
Squalene, botryococcene and their methylated derivatives 
from B. braunii have attracted signi?cant attention because 
these molecules are thought to be the progenitors to current 
oil shale deposits (Summons et al., Organic Geochem., 33: 
99-109, 2002; Walters et al., AAPG Bulletin, 89: 1239-1244, 
2005) and because they are considered promising renewable, 
alternative biofuels (Banerjee et al., Crit. Rev. Biolech., 22: 
245-279 (2002)). For example, Hillen et al. (Biotech. 
Bioeng., 24: 193-205, 1982) previously reported on the cata 
lytic cracking of oils extracted from Botryococcus braunii, 
primarily the methylated botryococcenes and squalene 
derivatives, and observed an overall conversion of 79% of the 
oil to combustible fuels under standard cracking conditions. 
Overall, 67% of the converted oil was to gasoline grade fuel 
(octanes), 15% to aviation turbine fuel, and 15% to diesel fuel 
with a residual of only 3%. Hence, catalytic hydrolysis (as 
performed in standard petroleum re?neries) of these highly 
branched, poly-unsaturated triterpenes results in the genera 
tion of hydrocarbon fractions that are chemically equivalent 
to those derived from current petroleum deposits and are of 
direct utility as fuels for internal combustion engines, as well 
as feedstocks for chemical manufacturing (Banerjee et al., 
2002). 
These energy-rich triterpene oils have only been available 
from cultures of Bolryococcus braunii, a rather slow growing 
green algae that does not lend itself to large-scale or fermen 
tation type culturing conditions (Casadevall et al., Biolech. 
Bioeng., 27: 286-295 (1985)). Thus, there is a need for 
improved sources of these energy-rich triterpene oils. 
SUMMARY OF THE INVENTION 
In one aspect, the present invention relates to an isolated 
polypeptide which is a triterpene methyltransferase, for 
example a Bolryococcus braunii triterpene methyltransferase 
comprising the amino acid sequence of SEQ ID NO:2 as well 
as variants, conservative variants, and fragments thereof. 
Another aspect of the present invention relates to an iso 
lated nucleic acid molecule that encodes a polypeptide of this 
invention, e.g., isolated nucleic acid molecule encoding SEQ 
ID NO: 2 and conservative variants and fragments thereof 
including, e.g., SEQ ID NO: 1. 
In another aspect, the present invention provides a vector 
comprising a nucleic acid molecule(s) of this invention that 
encodes a triterpene methyltransferase polypeptide of this 
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invention. In yet another aspect, the present invention pro 
vides a host cell transfected with the aforementioned nucleic 
acid molecule or vector. 
In another aspect, the present invention provides a method 
of producing a methylated triterpene of this invention. The 
method comprises providing a metabolizable carbon source 
to a host cell transfected with a nucleic acid molecule of this 
invention that encodes a triterpene methyltransferase under 
conditions suf?cient for production of a methylated triter 
pene. The method optionally further comprises isolating the 
methylated triterpene produced by the host cell. 
Other methods, features and advantages of the present 
invention will be or become apparent to one with skill in the 
art upon examination of the following detailed descriptions. It 
is intended that all such additional methods, features and 
advantages be included within this description, be within the 
scope of the present invention, and be protected by the accom 
panying claims. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows the DNA sequence for the B. braunii triter 
pene methyltransferase cDNA SEQ ID NO: 1. The start and 
stop codons are shown in bold. 
FIG. 2 shows the predicted amino acid sequence for the B. 
braunii triterpene methyltransferase protein, SEQ ID NO: 2. 
FIG. 3 illustrates a comparison of putative SAM (S-adeno 
syl methionine) and SMT (sterol methyltransferase speci?c) 
binding motifs in sterol methyltransferase genes from a vari 
ety of plants and Bolryococcus braunii triterpene methyl 
transferase. Peptide domain sequences 5'-3' for: B. braunii 
SEQ ID NO: 14, 15, 16, 17 and 18; N. tabacum SEQ ID NO: 
19, 20, 21, 22 and 23; A. lhalina SEQ ID NO: 24, 25, 26, 27; 
and 28 Z. mays SEQ ID NO: 29, 30, 31, 32; and 33 Osaziva 
SEQ ID NO: 34, 35, 36, 37 and 38; S. cerevisiae SEQ ID NO: 
39, 40, 41, 42 and 43. 
FIG. 4 shows TLC separation of reaction products gener 
ated upon incubation of extracts from bacteria over-express 
ing the TMT gene with (?lled circle symbols) and without 
squalene (open circle symbols). Extracts of bacteria trans 
formed with empty vector (no TMT gene) were also incu 
bated under identical conditions with (?lled square symbols) 
and without (open square symbols) squalene addition. Reac 
tions products extracted from the respective reactions were 
separated by reverse phase TLC and the radioactivity associ 
ated with the indicated zones determined by scintillation 
counting. 
FIG. 5 illustrates that methylated squalene formation is 
S-adenosylmethionine (SAM) dependent. An extract from 
bacteria over-expressing the TMT cDNA was incubated with 
20 mM squalene and the indicated concentrations of (3H 
methyl)-SAM for 30 min before separation of the methylated 
squalene products by reverse phase TLC. Zones of the TLC 
plate corresponding to where the methylated squalene 
migrated were scraped into scintillation vials, the radioactiv 
ity associated with these zone determined by scintillation 
counting and the amount of methylated squalene formed cal 
culated on the basis of the radioactivity incorporated. 
FIG. 6 shows the time dependency of TMT activity. 
FIG. 7 illustrates the pH dependency of TMT activity. 
FIG. 8 shows that TMT activity is extract amount depen 
dent. 
FIG. 9 shows the temperature dependency of TMT activity. 
FIG. 10 illustrates the squalene substrate dependency of 
TMT activity. 
FIG. 11 shows the C30 botryococcene dependency of TMT 
activity. 
US 8,704,040 B2 
3 
FIG. 12 illustrates the lack of lanosterol substrate depen 
dency of TMT activity. 
FIG. 13 demonstrates by SDS-PAGE the IPTG inducible 
expression of TMT in E. coli by the accumulation of an 
appropriate sized protein (approximately 120 kD) and the 
partial puri?cation of the TMT protein based on a hexa 
histidine tag appended to the amino terminus of the NUS 
TMT construct. 
FIG. 14 shows the GC-FID detection of squalene and 
methylated squalenes in yeast over-expressing cDNAs for B. 
braunii squalene synthase only (A), B. braunii triterpene 
methyltransferase only (B), or both squalene synthase and 
triterpene methyltransferase (C). Hexane extracts of the yeast 
cultures were prepared, concentrated, and analyzed by GC 
FID. Compound identi?cation was based on GC retention 
times reported by Achitouv et al. (2004) Phylochemislry, 65: 
3159-3165 (incorporated herein by reference). 
FIG. 15 shows the GC-MS detection of squalene and 
methylated squalene in yeast cultures over-expressing 
squalene synthase only (b) or squalene synthase plus triter 
pene methyltransferase (a). 
FIG. 16 depicts the lack of accumulation of methylated 
squalene derivatives in yeast cells over-expressing only the B. 
braunii squalene synthase (FIG. 16, panel A) or as compared 
to yeast cells expressing both the B. braunii squalene syn 
thase and triterpene methyltransferase genes (FIG. 16, panel 
B). 
FIG. 17 depicts the accumulation of mono- and di-methy 
late squalene in a time dependent manner. 
DETAILED DESCRIPTION OF THE INVENTION 
Before the present compositions and methods are 
described, it is to be understood that the invention is not 
limited to the particular methodologies, protocols, assays, 
and reagents described, as these may vary. It is also to be 
understood that the terminology used herein is intended to 
describe particular embodiments of the present invention, and 
is in no way intended to limit the scope of the present inven 
tion as set forth in the appended claims. 
It must be noted that as used herein and in the appended 
claims, the singular forms “a,” “an,” and “the” include plural 
references unless the context clearly dictates otherwise. 
Unless de?ned otherwise, all technical and scienti?c terms 
used herein have the same meanings as commonly under 
stood by one of ordinary skill in the art to which this invention 
belongs. All publications cited herein are incorporated herein 
by reference in their entirety for the purpose of describing and 
disclosing the methodologies, reagents, and tools reported in 
the publications that might be used in connection with the 
invention. Nothing herein is to be construed as an admission 
that the invention is not entitled to antedate such disclosure by 
virtue of prior invention. 
The present inventors have discovered an improved source 
of energy-rich triterpene oils. Among other things, the present 
inventors provide elucidation of the structural and functional 
characteristics of a triterpene methyltransferase gene from 
Botryococcus braunii. The B. braunii triterpene methyltrans 
ferase can be used to produce methylated linear triterpene 
hydrocarbons such as methylated botryococcenes and methy 
lated squalenes. 
These methylated botryococcenes and squalenes can be 
easily converted into high octane fuel for use in combustion 
engines. Because of this, B. braunii has attracted much inter 
est as a potential renewable fuel source. However, due to its 
slow growing nature and aquatic habitat, cultivation of B. 
braunii for hydrocarbon production remains technically and 
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economically dif?cult. The compositions and methods 
described herein provide a mechanism to overcome these 
dif?culties. 
Described herein are the nucleotide and amino acid 
sequences and functional characterization of a triterpene 
methyltransferase gene which, when expressed in a heterolo 
gous host such as a bacteria, yeast or plant, provides an 
enzyme activity that catalyzes the successive methylation of 
linear triterpene hydrocarbons such as squalene and botryo 
coccene, generating branched-chain hydrocarbons. The 
encoded methyltransferase activity can methylate squalene, 
for example, 1 to 4 times, generating mono-, di-, tri- and 
tetra-methylated squalenes derivatives. Botryococcene can 
likewise be methylated to form, for example, mono-, di-, tri 
and tetra-methylated botryococcenes. 
The identi?cation of the triterpene methyltransferase 
nucleic acid molecule and its encoded polypeptide, e.g. a 
polypeptide comprising the sequence set forth in SEQ ID NO: 
2 or a variant or fragment thereof having triterpene methyl 
transferase activity, provides a means of generating important 
raw materials for the reliable and cost effective production of 
an energy-rich, renewable, and sustainable biofuel source. 
For example, the co-expression of the triterpene methyltrans 
ferase in combination with suitable famesyl diphosphate 
(FPP) synthase and triterpene synthase in transgenic terres 
trial plants could yield a production platform for methylated 
triterpenes. These compounds would be derived from the 
metabolic diversion of CO2 ?xed in the process of photosyn 
thesis ?owing directly into triterpene biosynthesis and accu 
mulation. 
Thus, in one aspect the present invention provides a nucleic 
acid molecule encoding a triterpene methyltransferase. In 
another aspect, the present invention provides a polypeptide 
encoded by a triterpene methyltransferase nucleic acid mol 
ecule. A triterpene methyltransferase polypeptide can methy 
late a triterpene, e.g., squalene or botryococcene, to generate 
a mono-, di-, tri- or tetra-methylated triterpene. A triterpene 
methyltransferase from any species may be used, including 
an algal triterpene methyltransferase, such as a Botryococcus 
braunii triterpene methyltransferase. For example, FIG. 1 
shows the DNA sequence encoding a B. braunii triterpene 
methyltransferase of this invention (SEQ ID NO: 1), and FIG. 
2 shows the amino acid sequence of a B. braunii triterpene 
methyltransferase of this invention (SEQ ID NO:2). It should 
be understood that the invention is not limited to use of 
triterpene methyltransferase sequences of SEQ ID NO:l or 
SEQ ID N012. That is, any naturally-occurring triterpene 
methyltransferase may be used, whether derived from B. 
braunii or any other algal or other organism. In addition to 
naturally-occurring triterpene methyltransferase, synthetic 
variants of SEQ ID NO:l or SEQ ID NO:2 may be employed. 
While these variants will be described in more detail below, 
it is understood that polypeptides of the invention may con 
tain one or more modi?ed amino acids. The presence of 
modi?ed amino acids may be advantageous in, for example, 
increasing triterpene methyltransferase catalytic activity or 
increasing polypeptide stability. Amino acid(s) are modi?ed, 
for example, co-translationally or post-translationally during 
recombinant production (e.g., N-linked glycosylation at 
NiXiS/T motifs during expression in mammalian cells) or 
modi?ed by synthetic means. Accordingly, a “mutant”, “vari 
ant” or “modi?ed” protein, enzyme, polynucleotide, gene, or 
cell, means a protein, enzyme, polynucleotide, gene, or cell, 
that has been altered or derived, or is in some way different or 
changed, from a parent protein, enzyme, polynucleotide, 
US 8,704,040 B2 
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gene, or cell. A mutant or modi?ed protein or enzyme is 
usually, although not necessarily, expressed from a mutant 
polynucleotide or gene. 
A “parent” protein, enzyme, polynucleotide, gene, or cell, 
is any protein, enzyme, polynucleotide, gene, or cell, from 
which any other protein, enzyme, polynucleotide, gene, or 
cell, is derived or made, using any methods, tools or tech 
niques, and whether or not the parent is itself native or mutant. 
A parent polynucleotide or gene encodes for a parent protein 
or enzyme. 
A “mutation” means any process or mechanism resulting 
in a mutant protein, enzyme, polynucleotide, gene, or cell. 
This includes any mutation in which a protein, enzyme, poly 
nucleotide, or gene sequence is altered, and any detectable 
change in a cell arising from such a mutation. Typically, a 
mutation occurs in a polynucleotide or gene sequence, by 
point mutations, deletions, or insertions of single or multiple 
nucleotide residues. A mutation includes polynucleotide 
alterations arising within a protein-encoding region of a gene 
as well as alterations in regions outside of a protein-encoding 
sequence, such as, but not limited to, regulatory or promoter 
sequences. A mutation in a gene can be “silent”, i.e., not 
re?ected in an amino acid alteration upon expression, leading 
to a “sequence-conservative” variant of the gene. This gener 
ally arises when one amino acid corresponds to more than one 
codon. 
Non-limiting examples of a modi?ed amino acid include a 
glycosylated amino acid, a sulfated amino acid, a prenlyated 
(e. g., farnesylated, geranylgeranylated) amino acid, an acety 
lated amino acid, an acylated amino acid, a pegylated amino 
acid, a biotinylated amino acid, a carboxylated amino acid, a 
phosphorylated amino acid, and the like. References 
adequate to guide one of skill in the modi?cation of amino 
acids are replete throughout the literature. Example protocols 
are found in Walker (1998) Protein Protocols on CD-ROM 
(Humana Press, Towata, N.J.). 
Recombinant methods for producing and isolating modi 
?ed triterpene methyltransferase polypeptides of the inven 
tion are described herein. In addition to recombinant produc 
tion, the polypeptides may be produced by direct peptide 
synthesis using solid-phase techniques (e.g., Stewart et al. 
(1969) Solid-Phase Peptide Synthesis (WH Freeman Co, San 
Francisco); and Merri?eld (1963) J. Am. Chem. Soc. 851 
2149-2154; each of which is incorporated by reference). Pep 
tide synthesis may be performed using manual techniques or 
by automation. Automated synthesis may be achieved, for 
example, using Applied Biosystems 431A Peptide Synthe 
sizer (Perkin Elmer, Foster City, Calif.) in accordance with 
the instructions provided by the manufacturer. 
A “protein” or “polypeptide”, which terms are used inter 
changeably herein, comprises one or more chains of chemical 
building blocks called amino acids that are linked together by 
chemical bonds called peptide bonds. An “enzyme” means 
any substance, composed wholly or largely of protein, that 
catalyzes or promotes, more or less speci?cally, one or more 
chemical or biochemical reactions. The term “enzyme” can 
also refer to a catalytic polynucleotide (e.g., RNA or DNA).A 
“native” or “wild-type” protein, enzyme, polynucleotide, 
gene, or cell, means a protein, enzyme, polynucleotide, gene, 
or cell that occurs in nature. 
Accordingly, this invention also provides in various 
embodiments, isolated or recombinant polypeptides compris 
ing the amino acid sequence set forth in SEQ ID N012, an 
amino acid sequence that is at least 20%, 30%, 33%, 35%, 
37%, 40%, 44%, 50%, 53%, 60%, 70%, 80%, 90%, 95% and 
99% identical to the full-length amino acid sequence of SEQ 
ID N012, and polypeptides comprising SEQ ID N01 2 except 
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that up to e.g., 35, 25, 10, 5, 4, 3, 2 or 1 ofthe amino acids of 
SEQ ID N012 are conservative amino acid substitutions. 
Preferably the polypeptides have triterpene methyltrans 
ferase activity, e.g. approximately the level of triterpene 
methyltransferase activity of a polypeptide of SEQ ID N01 2, 
or higher than such level. 
“Conservative amino acid substitutions” of a particular 
sequence refers to the replacement of one amino acid, or 
series of amino acids, with essentially identical amino acid or 
series of amino acids. One of skill will recognize that indi 
vidual substitutions, deletions or additions which alter, add or 
delete a single amino acid or a percentage of amino acids in an 
encoded sequence result in “conservative variations” where 
the alterations result in the deletion of an amino acid, addition 
of an amino acid, or substitution of an amino acid with a 
functionally similar amino acid. 
Conservative substitution tables providing functionally 
similar amino acids are well known in the art. For example, 
one conservative substitution group includes Alanine (A), 
Serine (S), and Threonine (T). Another conservative substi 
tution group includes Aspartic acid (D) and Glutamic acid 
(E). Another conservative substitution group includes Aspar 
agine (N) and Glutamine (Q). Yet another conservative sub 
stitution group includesArginine (R) and Lysine (K). Another 
conservative substitution group includes Isoleucine, (I) Leu 
cine (L), Methionine (M), and Valine (V). Another conserva 
tive substitution group includes Phenylalanine (F), Tyrosine 
(Y), and Tryptophan (W). 
Thus, “conservative amino acid substitutions” of a listed 
polypeptide sequence (e.g., SEQ ID N012) include substitu 
tions of a percentage, typically less than 15% or less than 
10%, of the amino acids of the polypeptide sequence, with an 
amino acid of the same conservative substitution group. 
Accordingly, a conservatively substituted variation of a 
polypeptide of the invention can contain, for example, sub 
stitutions ofe.g., 40, 35, 25, 10, 5, 4, 3, 2 or 1 amino acidwith 
an amino acid of the same conservative substitution group. 
It is understood that the addition of sequences that do not 
alter the encoded activity of a nucleic acid molecule, such as 
the addition of a non-functional or non-coding sequence, is a 
conservative variation of the basic nucleic acid molecule. The 
“activity” of an enzyme is a measure of its ability to catalyze 
a reaction, i.e., to “function”, and may be expressed as the rate 
at which the product of the reaction is produced. For example, 
enzyme activity can be represented as the amount of product 
produced per unit of time or per unit of enzyme (e.g., con 
centration or weight), or in terms of af?nity or dissociation 
constants. As used interchangeably herein a “triterpene meth 
yltransferase activity”, “biological activity of triterpene 
methyltransferase” or “functional activity of triterpene meth 
yltransferase”, refers to an activity exerted by a triterpene 
methyltransferase protein, polypeptide or nucleic acid mol 
ecule on a triterpene methyltransferase polypeptide substrate, 
as determined in vivo, or in vitro, according to standard tech 
niques. 
One of skill in the art will appreciate that many conserva 
tive variations of the nucleic acid constructs which are dis 
closed herein yield a functionally identical construct. For 
example, owing to the degeneracy of the genetic code, “silent 
substitutions” (i.e., substitutions in a nucleic acid sequence 
which do not result in an alteration in an encoded polypep 
tide) are an implied feature of every nucleic acid sequence 
which encodes an amino acid. Similarly, “conservative amino 
acid substitutions,” in one or a few amino acids in an amino 
acid sequence are substituted with different amino acids with 
highly similar properties, are also readily identi?ed as being 
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highly similar to a disclosed construct. Such conservative 
variations of each disclosed sequence are a feature of the 
polypeptides provided herein. 
It will be appreciated by those skilled in the art that due to 
the degeneracy of the genetic code, a multitude of nucleotide 
sequences encoding modi?ed triterpene methyltransferase 
polypeptides of the invention may be produced, some of 
which bear substantial identity to the nucleic acid sequences 
explicitly disclosed herein. For instance, codons AGA, AGG, 
CGA, CGC, CGG, and CGU all encode the amino acid argi 
nine. Thus, at every position in the nucleic acid molecules of 
the invention where an arginine is speci?ed by a codon, the 
codon can be altered to any of the corresponding codons 
described above without altering the encoded polypeptide. It 
is understood that U in an RNA sequence corresponds to T in 
a DNA sequence. 
“Conservative variants” are proteins or enzymes in which a 
given amino acid residue has been changed without altering 
overall conformation and function of the protein or enzyme, 
including, but not limited to, replacement of an amino acid 
with one having similar properties, including polar or non 
polar character, size, shape and charge. Amino acids other 
than those indicated as conserved may differ in a protein or 
enzyme so that the percent protein or amino acid sequence 
similarity between any two proteins of similar function may 
vary and can be, for example, at least 30%, at least 32%, at 
least 37%, at least 44%, at least 50%, at least 53%, at least 
70%, at least 80%, at least 90%, at least 95%, at least 98% or 
at least 99%, as determined according to an alignment 
scheme. As referred to herein, “sequence similarity” means 
the extent to which nucleotide or protein sequences are 
related. The extent of similarity between two sequences can 
be based on percent sequence identity and/or conservation. 
“Sequence identity” herein means the extent to which two 
nucleotide or amino acid sequences are invariant. “Sequence 
alignment” means the process of lining up two or more 
sequences to achieve maximal levels of identity (and, in the 
case of amino acid sequences, conservation) for the purpose 
of assessing the degree of similarity. Numerous methods for 
aligning sequences and assessing similarity/identity are 
known in the art such as, for example, the Cluster Method, 
wherein similarity is based on the MEGALIGN algorithm, as 
well as BLASTN, BLASTP, and FASTA (Lipman and Pear 
son, 1985 Science 22; 227(4693):1435-41; Pearson and Lip 
man, 1988 Proc Natl Acad Sci USA, 85(8):2444-8). When 
using all of these programs, the preferred settings are those 
that results in the highest sequence similarity. 
Non-conservative modi?cations of a particular polypep 
tide are those which substitute any amino acid not character 
ized as a conservative substitution. For example, any substi 
tution which crosses the bounds of the six groups set forth 
above. These include substitutions of basic or acidic amino 
acids for neutral amino acids, (e.g., Asp, Glu, Asn, or Gln for 
Val, Ile, Leu or Met), aromatic amino acid for basic or acidic 
amino acids (e.g., Phe, Tyr or Trp for Asp, Asn, Glu or Gln) or 
any other substitution not replacing an amino acid with a like 
amino acid. Basic amino acids include lysine (K), arginine 
(R), histidine (H); acidic amino acids include aspartic acid 
(D), glutamic acid (E); uncharged polar amino acids include 
glycine (G), asparagine (N), glutamine (Q), serine (S), threo 
nine (T), tyrosine (Y), cysteine (C); nonpolar amino acids 
include alanine (A), valine (V), leucine (L), isoleucine (I), 
proline (P), phenylalanine (F), methionine (M), tryptophan 
(W); beta-branched amino acids include threonine (T), valine 
(V), isoleucine (I); aromatic amino acids include tyrosine 
(Y), phenylalanine (F), tryptophan (W), histidine (H). 
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A polynucleotide, polypeptide, or other component is “iso 
lated” when it is partially or completely separated from com 
ponents with which it is normally associated (other proteins, 
nucleic acid molecules, cells, synthetic reagents, etc.). A 
nucleic acid molecule or polypeptide is “recombinant” when 
it is arti?cial or engineered, or derived from an arti?cial or 
engineered protein or nucleic acid molecule. For example, a 
polynucleotide that is inserted into a vector or any other 
heterologous location, e.g., in a genome of a recombinant 
organism, such that it is not associated with nucleotide 
sequences that normally ?ank the polynucleotide as it is 
found in nature is a recombinant polynucleotide. A protein 
expressed in vitro or in vivo from a recombinant polynucle 
otide is an example of a recombinant polypeptide. Likewise, 
a polynucleotide sequence that does not appear in nature, for 
example a variant of a naturally occurring gene, is recombi 
nant. For example, an “isolated” nucleic acid molecule is one 
which is separated from other nucleic acid molecules which 
are present in the natural source of the nucleic acid molecule. 
For example, with regards to genomic DNA, the term “iso 
lated” includes nucleic acid molecules which are separated 
from the chromosome with which the genomic DNA is natu 
rally associated. Typically, an “isolated” nucleic acid mol 
ecule is free of sequences which naturally ?ank the nucleic 
acid molecule (i.e., sequences located at the 5' and 3' ends of 
the nucleic acid molecule) in the genomic DNA of the organ 
ism from which the nucleic acid molecule is derived. For 
example, in various embodiments, the isolated nucleic acid 
molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 
kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally 
?ank the nucleic acid molecule in genomic DNA of the cell 
from which the nucleic acid molecule is derived. Moreover, 
an “isolated” nucleic acid molecule, such as a cDNA mol 
ecule, can be substantially free of other cellular material, or 
culture medium when produced by recombinant techniques, 
or substantially free of chemical precursors or other chemi 
cals when chemically synthesized. 
In some embodiments, a polypeptide provided herein 
includes amino acid residue substitutions that correspond to 
positions in a particular sequence at least 80%, 85%, 90%, 95, 
98 or 99% of the time. In other words, the invention encom 
passes polypeptides that contain the recited amino acid sub 
stitutions at 80%, 85%, 90%, 95, 98 or 99% of the recited 
positions in a given sequence. The skilled artisan will recog 
nize that not every substitution from a group of substitutions 
is necessary to obtain a modi?ed polypeptide that is active on 
a triterpene substrate. 
“Sequence identity” herein means the extent to which two 
nucleotide or amino acid sequences are invariant. “Sequence 
alignment” means the process of lining up two or more 
sequences to achieve maximal levels of identity (and, in the 
case of amino acid sequences, conservation) for the purpose 
of assessing the degree of similarity. Numerous methods for 
aligning sequences and assessing similarity/ identity are 
known in the art such as, for example, the Cluster Method, 
wherein similarity is based on the MEGALIGN algorithm, as 
well as BLASTN, BLASTP, and FASTA (Lipman and Pear 
son, 1985; Pearson and Lipman, 1988). When using all of 
these programs, the preferred settings are those that results in 
the highest sequence similarity. For example, the “identity” or 
“percent identity” with respect to a particular pair of aligned 
amino acid sequences can refer to the percent amino acid 
sequence identity that is obtained by ClustalW analysis (ver 
sion W 1.8 available from European Bioinformatics Institute, 
Cambridge, UK, counting the number of identical matches in 
the alignment and dividing such number of identical matches 
by the greater of (i) the length of the aligned sequences, and 
US 8,704,040 B2 
(ii) 96, and using the following default ClustalW parameters 
to achieve slow/accurate pairwise alignments4Gap Open 
Penalty: 10; Gap Extension Penalty: 0.10; Protein weight 
matrix: Gonnet series; DNA weight matrix: IUB; Toggle 
Slow/Fast pairwise alignmentsISLOW or FULL Alignment. 
See also Larkin M A, Blackshields G, Brown N P, Chema R, 
McGettigan P A, McWilliam H, Valentin E, Wallace I M, 
Wilm A, LopeZ R, Thompson J D, Gibson T J, Higgins D G. 
(2007). Clustal W and Clustal X version 2.0. Bioinformalics, 
23, 2947-2948.) 
Two sequences are “optimally aligned” when they are 
aligned for similarity scoring using a de?ned amino acid 
substitution matrix (e.g., BLOSUM62), gap existence pen 
alty and gap extension penalty so as to arrive at the highest 
score possible for that pair of sequences. Amino acid substi 
tution matrices and their use in quantifying the similarity 
between two sequences are well-known in the art and 
described, e.g., in Dayhoff (1978) “A model of evolutionary 
change in proteins” in “Atlas of Protein Sequence and Struc 
ture,”Vol. 5, Suppl. 3 (ed. M. O. Dayhoff), pp. 345-352. Natl. 
Biomed. Res. Found, Washington, DC. and Henikoff et al. 
(1992) Proc. Natl. Acad. Sci. USA 89: 10915-10919 (each of 
which is incorporated in its entirety by reference). The BLO 
SUM62 matrix is often used as a default scoring substitution 
matrix in sequence alignment protocols such as Gapped 
BLAST 2.0. The gap existence penalty is imposed for the 
introduction of a single amino acid gap in one of the aligned 
sequences, and the gap extension penalty is imposed for each 
additional empty amino acid position inserted into an already 
opened gap. The alignment is de?ned by the amino acids 
positions of each sequence at which the alignment begins and 
ends, and optionally by the insertion of a gap or multiple gaps 
in one or both sequences so as to arrive at the highest possible 
score. While optimal alignment and scoring can be accom 
plished manually, the process is facilitated by the use of a 
computer-implemented alignment algorithm, e.g., gapped 
BLAST 2.0, described in Altschul et al. (1997) Nucl. Acids 
Res. 25: 3389-3402 (incorporated by reference herein), and 
made available to the public at the National Center for Bio 
technology Inforrnation (NCBI) Website (www.ncbi.nlm.ni 
h.gov). Optimal alignments, including multiple alignments, 
can be prepared using, e.g., PSI-BLAST, available through 
the NCB1 website and described by Altschul et al. (1997) 
Nucl. Acids Res. 25:3389-3402 (incorporated by reference 
herein). 
With respect to an amino acid sequence that is optimally 
aligned with a reference sequence, an amino acid residue 
“corresponds to” the position in the reference sequence with 
which the residue is paired in the alignment. The “position” is 
denoted by a number that sequentially identi?es each amino 
acid in the reference sequence based on its position relative to 
the N-tenninus. For example, in SEQ ID NO:2 as the refer 
ence sequence, position 1 is M, position 2 isA, position 3 is L, 
etc. When a test sequence is optimally aligned with SEQ ID 
NO:2, a residue in the test sequence that aligns with the L at 
position 3 is said to “correspond to position 3” of SEQ ID 
NO:2. Owing to deletions, insertion, truncations, fusions, 
etc., that must be taken into account when determining an 
optimal alignment, in general the amino acid residue number 
in a test sequence as determined by simply counting from the 
N-terminal will not necessarily be the same as the number of 
its corresponding position in the reference sequence. For 
example, in a case where there is a deletion in an aligned test 
sequence, there will be no amino acid that corresponds to a 
position in the reference sequence at the site of deletion. 
Where there is an insertion in an aligned reference sequence, 
that insertion will not correspond to any amino acid position 
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in the reference sequence. In the case of truncations or fusions 
there can be stretches of amino acids in either the reference or 
aligned sequence that do not correspond to any amino acid in 
the corresponding sequence. 
Also contemplated are fragments of the full length triter 
pene methyltransferase polypeptides and polynucleotides, 
e.g., fragments of polypeptides, wherein the polypeptide 
comprises the amino acid sequence set forth in SEQ ID NO: 
2 and fragments of nucleic acid molecules, wherein the 
nucleic acid molecules comprises the sequence set forth in 
SEQ ID NO: 1. For example a fragment of this invention is a 
fragment of SEQ ID NO: 2 or SEQ ID NO: 1 comprising the 
SMT-II domain, SEQ ID NO:17, or encoding the SMT-II 
domain. A “fragment” is a unique portion of a triterpene 
methyltransferase polypeptide or the polynucleotide encod 
ing triterpene methyltransferase which is identical in 
sequence to, but shorter in length than, the parent sequence. A 
fragment may comprise up to the entire length of the de?ned 
sequence, minus one nucleotide/amino acid residue. For 
example, a fragment may comprise from 5 to 1000 contigu 
ous nucleotides or amino acid residues of a given nucleic acid 
molecule or polypeptide. A fragment used as a probe, primer, 
antigen, catalytic molecule, or for other purposes, may be at 
least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or 
at least 500 contiguous nucleotides or amino acid residues in 
length. Fragments may be preferentially selected from certain 
regions of a molecule. For example, a polypeptide fragment 
may comprise a certain length of contiguous amino acids 
selected from the ?rst 250 or 500 amino acids (or ?rst 25% or 
50%) of a polypeptide as shown in a certain de?ned sequence. 
Clearly these lengths are exemplary, and any length that is 
supported by the speci?cation, including the Sequence List 
ing, tables, and ?gures, may be encompassed by the present 
embodiments. 
Also contemplated in this invention are isolated polypep 
tides that are methyltransferases, preferably triterpene meth 
yltransferases, that comprise 5 peptide domains, each peptide 
domain comprising at least 9 amino acids, wherein three of 
the domains, SAM-I, SAM-II and SAM-III, are associated 
with binding of a common methyl donor (SAM binding 
domains), and two peptide domains, SMT-I and SMT-II, are 
associated with catalytic transfer of methyl substituents from 
a methyl donor to a methyl acceptor. The SMT-I, SAM-I, 
SAM-II, SMT-II and SAM-III domains of the triterpene 
methyltransferases of this invention may comprise respec 
tively, e.g., SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, 
SEQ ID NO: 17 and SEQ ID NO: 18 (See FIG. 3, the 5 
domains of B. braunii). In an embodiment of the invention, 
the SMT-I domain comprises an amino acid sequence that is 
at least 20%, 30%, 40%, 50%, 60%, 62%, 70%, 77%, 80%, 
90% or 95% identical to the full-length of SEQ ID NO: 14, the 
SAM-I domain comprises an amino acid sequence that is at 
least 20%, 30%, 38%, 40%, 50%, 60%, 63%, 70%, 78%, 
80%, 89%, 90% or 95% identical the full-length of SEQ ID 
NO: 15, the SAM-II peptide domain may comprises an amino 
acid sequence that is at least 20%, 30%, 40%, 50%, 60%, 
63%, 70%, 80%, 90% or 95% identical to the full-length of 
SEQ ID NO: 16, the SMT-II peptide domain comprises an 
amino acid sequence that is at least 20%, 30%, 40%, 50%, 
60%, 70%, 80%, 90% or 95% identical to the full-length of 
SEQ ID NO: 17 and the SAM-III peptide domain comprises 
an amino acid sequence that is at least 20%, 30%, 40%, 50%, 
60%, 70%, 80%, 90% or 95% identical the full-length ofSEQ 
ID NO: 18. The SMT-II peptide domain may also comprise an 
amino acid sequence that is at least 20%, 30%, 40%, 50%, 
60%, 63%, 70%, 80%, 90% or 95% identical to the full-length 
of SEQ ID NO: 16, with the proviso that the sequence does 
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not comprise amino acid sequence IEATCHAP (SEQ ID NO: 
22). The 5 peptide domains may be present in the methyl 
transferase in any order, preferably the order of the 5 peptides 
in the polypeptide is, from its amino to carboxy terminal, 
SMT-I, SAM-I, SAM-II, SMT-II and SAM-III, and more 
preferably the SMT-I, SAM-I, SAM-II, SMT-II and SAM-III 
peptide domains comprise respectively the B. braunii 
sequences in FIG. 3, SEQ ID NO: 14, SEQ ID NO: 15, SEQ 
ID NO: 16, SEQ ID NO: 17 and SEQ ID NO: 18. 
In other embodiments, isolated nucleic acid molecules are 
provided. In one aspect, the invention provides a novel family 
of isolated or recombinant polynucleotides referred to herein 
as “triterpene methyltransferase polynucleotides” or “triter 
pene methyltransferase nucleic acid molecules.” Triterpene 
methyltransferase polynucleotide sequences are character 
ized by the ability to encode a triterpene methyltransferase 
polypeptide. In general, the invention includes any nucleotide 
sequence that encodes any of the novel triterpene methyl 
transferase polypeptides described herein. The invention pro 
vides nucleic acid molecules encoding a triterpene methyl 
transferase having the sequence set forth in SEQ ID NO: 2 or 
conservative variants thereof. In particular the invention pro 
vides nucleic acid molecules comprising SEQ ID NO: 1. The 
invention also provides isolated or recombinant polynucle 
otides that encode the polypeptide domains described herein. 
The terms “polynucleotide,” “nucleotide sequence,” and 
“nucleic acid molecule” are used to refer to a polymer of 
nucleotides (A, C, T, U, G, etc. or naturally occurring or 
arti?cial nucleotide analogues), e. g., DNA or RNA, or a rep 
resentation thereof, e.g., a character string, etc., depending on 
the relevant context. A given polynucleotide or polynucle 
otide complementary to the entire length of a given poly 
nucleotide can be determined from any speci?ed nucleotide 
sequence. 
In one aspect, the triterpene methyltransferase polynucle 
otides comprise recombinant or isolated forms of naturally 
occurring nucleic acid molecules isolated from an organism, 
e.g., an algae strain. Exemplary triterpene methyltransferase 
polynucleotides include those that encode the Wild-type 
polypeptide set forth in SEQ ID N012. In another aspect of the 
invention, triterpene methyltransferase polynucleotides are 
produced by diversifying, e.g., mutating a naturally occur 
ring, isolated, or recombinant triterpene methyltransferase 
polynucleotide. It is possible to generate diversi?ed triterpene 
methyltransferase polynucleotides encoding triterpene meth 
yltransferase polypeptides With superior functional 
attributes, e.g., increased catalytic function, increased stabil 
ity, or higher expression level, than a triterpene methyltrans 
ferase polynucleotide used as a substrate or parent in the 
diversi?cation process. 
The polynucleotides of the invention have a variety of uses 
in, for example recombinant production (i.e., expression) of 
the triterpene methyltransferase polypeptides of the invention 
and as substrates for further diversity generation, e. g., recom 
bination reactions or mutation reactions to produce neW and/ 
or improved triterpene methyltransferase homologues, and 
the like. 
It is important to note that certain speci?c, substantial and 
credible utilities of triterpene methyltransferase polynucle 
otides do not require that the polynucleotide encode a 
polypeptide With substantial triterpene methyltransferase 
activity or even variant triterpene methyltransferase activity. 
For example, triterpene methyltransferase polynucleotides 
that do not encode active enzymes can be valuable sources of 
parental polynucleotides for use in diversi?cation procedures 
to arrive at triterpene methyltransferase polynucleotide vari 
ants, or non-triterpene methyltransferase polynucleotides, 
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With desirable functional properties (e.g., high kcat or kcat/ 
Km, low Km, high stability towards heat or other environ 
mental factors, high transcription or translation rates, resis 
tance to proteolytic cleavage, etc.). 
Triterpene methyltransferase polynucleotides of this 
invention, including nucleotide sequences that encode triter 
pene methyltransferase polypeptides and variants thereof, 
fragments of triterpene methyltransferase polypeptides, 
related fusion proteins, or functional equivalents thereof, are 
used in recombinant DNA molecules that direct the expres 
sion of the triterpene methyltransferase polypeptides in 
appropriate host cells, such as plant cells. Due to the inherent 
degeneracy of the genetic code, other nucleic acid sequences 
Which encode substantially the same or a functionally equiva 
lent amino acid sequence can also be used to clone and 
express the triterpene methyltransferase polynucleotides. 
The term “host cell”, as used herein, includes any cell type 
Which is susceptible to transformation With a nucleic acid 
construct. The term “transformation” means the introduction 
of a foreign (i.e., extrinsic or extracellular) gene, DNA or 
RNA sequence to a host cell, so that the host cell Will express 
the introduced gene or sequence to produce a desired sub 
stance, typically a protein or enzyme coded by the introduced 
gene or sequence. The introduced gene or sequence may 
include regulatory or control sequences, such as start, stop, 
promoter, signal, secretion, or other sequences used by the 
genetic machinery of the cell. A host cell that receives and 
expresses introduced DNA or RNA has been “transformed” 
and is a “transforrnant” or a “clone.” The DNA or RNA 
introduced to a host cell can come from any source, including 
cells of the same genus or species as the host cell, or cells of 
a different genus or species. 
As Will be understood by those of skill in the art, it can be 
advantageous to modify a coding sequence to enhance its 
expression in a particular host. The genetic code is redundant 
With 64 possible codons, but most organisms preferentially 
use a subset of these codons. The codons that are utilized most 
often in a species are called optimal codons, and those not 
utilized very often are classi?ed as rare or low-usage codons 
(see, e.g., Zhang et al. (1991) Gene 105161-72; incorporated 
by reference herein). Codons can be substituted to re?ect the 
preferred codon usage of the host, a process sometimes called 
“codon optimization” or “controlling for species codon bias.” 
Optimized coding sequences containing codons preferred 
by a particular prokaryotic or eukaryotic host (see also, Mur 
ray et al. (1 989) Nucl. Acids Res. 17:477-508; incorporated by 
reference herein) can be prepared, for example, to increase 
the rate of translation or to produce recombinant RNA tran 
scripts having desirable properties, such as a longer half-life, 
as compared With transcripts produced from a non-optimized 
sequence. Translation stop codons can also be modi?ed to 
re?ect host preference. For example, preferred stop codons 
for S. cerevisiae and mammals are UAA and UGA, respec 
tively. The preferred stop codon for monocotyledonous plants 
is UGA, Whereas insects and E. coli prefer to use UAA as the 
stop codon (Dalphin et al. (1996) Nucl. Acids Res. 24: 216 
218; incorporated by reference herein). Methodology for 
optimizing a nucleotide sequence for expression in a plant is 
provided, for example, in US. Pat. No. 6,015,891, and the 
references cited therein, (incorporated herein by reference). 
“Silent variations” are one species of “conservative varia 
tions.” One of skill Will recognize that each codon in a nucleic 
acid sequence (except AUG, Which is ordinarily the only 
codon for methionine) can be modi?ed by standard tech 
niques to encode a functionally identical polypeptide. 
Accordingly, each silent variation of a nucleic acid sequence 
that encodes a polypeptide is implicit in any described 

















